genotypes

Daclatasvir (EBP 883) (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. Phase 3.

Dehydrojuncusol, a new inhibitor of hepatitis C virus RNA replication, it inhibits infection of different HCV genotypes by targeting the NS5A protein and is active against resistant HCV variants frequently found in patients with treatment failure.

PSI-7409 tetrasodium, the active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), exhibits specific inhibitory activity against NS5B polymerases of various genotypes, with IC50s being 1.6 μM for GT 1b_Con1, 2.8 μM for GT 2a_JFH1, 0.7 μM for GT 3a, and 2.6 μM for GT 4a, respectively.

Ciluprevir is an effective and selective HCV NS3 protease inhibitor with proven antiviral effect in humans. Ciluprevir may be an antiviral agent for individuals infected with non-genotype-1 HCV. In vitro sensitivity studies with Ciluprevir showed a decrea

Beclabuvir (BMS-791325) is a potent NS5A replication complex inhibitor that inhibits the activity of the NS5B protein expressed by HCV genotypes 1, 2, 4, and 5 and is used in the study of HCV infection.

ABT530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6.

(E)-10-Hydroxynortriptyline (E-10-OH-NT) is a metabolite of Nortriptyline . Nortriptyline is a tricyclic antidepressant and the main active metabolite of Amitriptyline, and is used to relieve the symptoms of depression[1]. [1]. Shimoda K, et al. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol. 2002 Aug;22(4):371-8. [2]. Shimoda K, et al. Dean L. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. Biotechnology Information (US); 2012-2017 Mar 23.

Beclabuvir, also known as BMS-791325, is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. BMS-791325 inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 at 50% inhibitory concentrations (IC50) below 28 nM. In cell culture, BMS-791325 inhibited replication of HCV subgenomic replicons representing genotypes 1a and 1b at 50% effective concentrations (EC50s) of 3 nM and 6 nM, respectively, with similar (3 to 18 nM) values for genotypes 3a, 4a, and 5a. B

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

The nucleocapsid of the hepatitis B virus is covered by an envelope of HBV surface antigen (HBsAg), which has the common, group-specific determinant a. The four major subtypes of HBsAg, adw, adr, ayw and ayr, are generated, and they have been proposed to

NS5A-IN-4 (Compound 1.12) is a pan-genotypic, orally active inhibitor of the hepatitis C virus (HCV) NS5A, exhibiting IC50 values of 1.2, 2296, 4.6, 362, 10.3, and 693 pM against genotypes gT1b, gT1a, gT2a, gT3a, gT4a, and gT5a, respectively [1].

HCV Core Protein (107-114), identified as the binding site within the region 101-118, is a minimally immunogenic fragment of the primary linear HCV core regions. This segment, comprising two residues that vary between genotypes I/II and III/VI, represents a potential focal point for the dissemination of HCV serotypes [1].

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].

Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Ki of 0.01 nM (gt1a), 0.08 nM (gt2a), 0.90 nM (gt3a), 0.01 nM (gt1b), 0.15 nM (gt2b), respectively.

SMCypIC31 is a non-peptide cyclophilin inhibitor that effectively inhibits peptidyl-prolyl cis/trans isomerase (PPIase) (IC50: 0.1 μM). SMCypI C31 has a pan-genotypic effect against HCV, with an EC50 range of 1.20-7.76 μM against genotypes 1a, 1b, 2a, 3a and 5a HCV-SGRs and chimeric genotypes 2a/4a HCV-SGRs.

BI-1388 is a highly potent inhibitor of HCV NS3 protease activity, inhibiting viral replication for various HCV genotypes and for resistant mutants D168V and R155K.

GSK-625433, a homochiral inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase, has the ability to inhibit the polymerase of both HCV genotypes 1a and 1b.

Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice.

Paritaprevir dihydrate (ABT-450), a highly effective and orally administered antiviral, acts as a non-structural protein 3/4A (NS3/4A) protease inhibitor, displaying EC50 values of 1 and 0.21 nM against HCV genotypes 1a and 1b, respectively. Additionally, it functions as a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Primarily metabolized by cytochrome P450 (CYP) 3A, its plasma concentration and half-life are significantly increased when administered with Ritonavir, a CYP450 inhibitor [1] [2] [3] [4].

HCV-IN-41 (compound 4), a potent inhibitor of the hepatitis C virus (HCV), demonstrates exceptional inhibitory effectiveness across different genotypes, with EC 50 values of 0.006762 nM for genotype 1b, 5.183 nM for 2a, 1.365 nM for 3a, and 142.2 nM for 4a, respectively. It effectively reduces HCV RNA replication [1].

7(Z)-Pentacosene is an unsaturated cuticular hydrocarbon that acts as a contact sex pheromone in fruit flies. In different species and genotypes of Drosophila, it can be found on both males and females. Pentacosene may stimulate copulation either by itself at high concentrations or when combined with other alkenes. Interestingly, the absolute level of pentacosene increases in Drosophila females immediately after copulation.

Ombitasvir (ABT-267) is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a

GSK-2336805 is a HCV NS5A inhibitor. GSK2336805 retained activity on chimeric replicons containing NS5A patient sequences from genotype 1 and patient and consensus sequences for genotypes 4 and 5 and part of genotype 6.

Velpatasvir (GS-5816), also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes.

Grazoprevir sodium salt is a selective Hepatitis C virus NS3/4a protease inhibitor with broad activity across genotypes and resistant variants.